These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 14998852)

  • 1. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
    Kornek GV; Schuell B; Laengle F; Gruenberger T; Penz M; Karall K; Depisch D; Lang F; Scheithauer W
    Ann Oncol; 2004 Mar; 15(3):478-83. PubMed ID: 14998852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
    Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
    Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
    Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
    Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
    Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.
    Jiménez-Fonseca P; Solis MP; Garrido M; Faez L; Rodriguez D; Ruiz AL; Sanchez Lorenzo ML; Uriol E; Menendez MD; Viéitez JM
    Clin Transl Oncol; 2015 May; 17(5):384-92. PubMed ID: 25428757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
    Raderer M; Hejna MH; Valencak JB; Kornek GV; Weinländer GS; Bareck E; Lenauer J; Brodowicz T; Lang F; Scheithauer W
    Oncology; 1999 Apr; 56(3):177-80. PubMed ID: 10202270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
    Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
    Koeberle D; Saletti P; Borner M; Gerber D; Dietrich D; Caspar CB; Mingrone W; Beretta K; Strasser F; Ruhstaller T; Mora O; Herrmann R;
    J Clin Oncol; 2008 Aug; 26(22):3702-8. PubMed ID: 18669455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
    Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
    Santini D; Virzi V; Vasile E; Vincenzi B; Catalano V; Graziano F; Masi G; Bronte G; Russo A; Falcone A; Tonini G
    Oncology; 2012; 82(2):75-82. PubMed ID: 22327844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
    Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
    Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
    Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
    Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.
    Kim HJ; Lee NS; Lee SC; Bae SB; Kim CK; Cheon YG; Kim YS; Moon JH; Cho YD; Park SH; Lee KT; Park SK; Won JH; Park HS; Hong DS
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):371-7. PubMed ID: 19142638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
    Tuinmann G; Hegewisch-Becker S; Zschaber R; Kehr A; Schulz J; Hossfeld DK
    Anticancer Drugs; 2004 Jul; 15(6):575-9. PubMed ID: 15205599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.